- Home
- CFR vs LEGN Comparison
CFR vs LEGN Comparison
Compare CFR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFR | LEGN |
|---|---|---|
| Founded | 1868 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CFR | LEGN |
|---|---|---|
| Price | $134.97 | $20.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $137.64 | $69.58 |
| AVG Volume (30 Days) | 418.5K | ★ 2.5M |
| Earning Date | 01-29-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | ★ 20.47 | N/A |
| EPS | ★ 9.72 | N/A |
| Revenue | ★ $2,141,575,000.00 | $909,045,000.00 |
| Revenue This Year | $14.17 | $68.52 |
| Revenue Next Year | $4.47 | $48.63 |
| P/E Ratio | $13.75 | ★ N/A |
| Revenue Growth | 9.02 | ★ 74.75 |
| 52 Week Low | $100.31 | $20.26 |
| 52 Week High | $146.44 | $45.30 |
Technical Indicators
Market Signals| Indicator | CFR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 70.45 | 31.83 |
| Support Level | $125.03 | $21.19 |
| Resistance Level | $129.17 | $22.07 |
| Average True Range (ATR) | 2.35 | 0.77 |
| MACD | 0.38 | 0.11 |
| Stochastic Oscillator | 96.23 | 25.71 |
Price Performance
Historical ComparisonAbout CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $53 billion in assets (as of September 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.